Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Dec 21, 2009; 15(47): 5946-5952
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Table 5 Time course evaluation of hemoglobin and creatinine serum levels during treatment (mean ± SD)
| PR group (n = 15) | PK group (n = 16) | PRK group (n = 14) | |
| Hemoglobin (g/dL) | |||
| Baseline | 14.5 ± 1.3 | 14.2 ± 1.9 | 14.9 ± 1.5 |
| Week 12 | 12.2 ± 1.4 | 12.5 ± 1.7 | 12.2 ± 1.6 |
| Week 24 | 12.2 ± 1.6 | 12.6 ± 1.8 | 11.9 ± 1.7 |
| Week 48 | 11.6 ± 1.4 | 13.1 ± 1.8 | 12.0 ± 1.6 |
| Creatinine (mg/dL) | |||
| Baseline | 0.97 ± 0.13 | 0.82 ± 0.22 | 1.01 ± 0.07 |
| Week 12 | 0.87 ± 0.11 | 0.82 ± 0.16 | 0.92 ± 0.12 |
| Week 24 | 0.86 ± 0.15 | 0.79 ± 0.16 | 0.91 ± 0.15 |
| Week 48 | 0.44 ± 0.15 | 0.80 ± 0.17 | 0.92 ± 0.15 |
- Citation: Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. World J Gastroenterol 2009; 15(47): 5946-5952
- URL: https://www.wjgnet.com/1007-9327/full/v15/i47/5946.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5946